Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Predictive Oncology Inc. (NASDAQ: POAI), which is changing its name to Axe Compute Inc. with an expected ticker change to AGPU, provides access to the company’s official regulatory disclosures. These documents include current reports on Form 8‑K, proxy statements, and other filings that describe material events, governance decisions, financing transactions, and listing matters.
Recent Form 8‑K filings detail several key developments. One 8‑K reports the adoption of a digital asset treasury strategy supported by private placements involving cash and in‑kind contributions of ATH, the native utility token of the Aethir ecosystem. Other 8‑Ks describe the launch and terms of these private placements, related registration rights agreements, and the use of proceeds to acquire ATH and support working capital and general corporate purposes. Additional 8‑Ks cover the 1‑for‑15 reverse stock split of the company’s common stock, actions taken to address Nasdaq listing requirements, and the company’s belief that it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement.
The filings also document corporate governance and shareholder matters. A definitive proxy statement on Schedule DEF 14A outlines proposals for the annual meeting, including the election of directors, ratification of the independent auditor, amendments to the 2024 Equity Incentive Plan, approval of the issuance of shares upon exercise of pre‑funded warrants, and a non‑binding advisory vote on executive compensation. Another 8‑K describes shareholder approval of these items and the resulting increase in shares available under the equity plan.
One notable 8‑K filing reports the corporate name change from Predictive Oncology Inc. to Axe Compute Inc., effective December 11, 2025, and states that the Nasdaq ticker symbol is expected to change from POAI to AGPU on or about December 12, 2025. The filing notes that outstanding stock certificates remain valid and that the CUSIP number for the common stock will not change in connection with the name change.
Through Stock Titan, users can review these SEC filings in sequence and, with AI‑powered summaries, quickly understand the implications of complex documents such as 8‑Ks, proxy statements, and registration‑related supplements. This includes identifying how financing structures, equity plans, reverse splits, and digital asset strategies affect the company’s capital structure and governance over time.
Predictive Oncology Inc. (POAI) reporting person Raymond F. Vennare, who serves as Chief Executive Officer and a director, received a grant of 124,959 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock upon vesting. The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through that date. Following the grant, the reporting person beneficially owns 132,081 shares of common stock as of the reported transaction. The Form 4 was signed on 09/11/2025 by an attorney-in-fact.
Joshua Blacher, identified as Interim CFO and an officer of Predictive Oncology Inc. (POAI), filed an initial Form 3 disclosing that he does not beneficially own any securities of the issuer. The report lists the relevant event date as 10/01/2023 and includes a signed remark that the Form 3 is being filed late due to an inadvertent administrative oversight; the filer states he is submitting the form promptly upon discovery and intends to comply with future Section 16(a) filing requirements. No non-derivative or derivative holdings are reported on this form.
Predictive Oncology Inc. is calling a special stockholder meeting on September 19, 2025 to vote on three key items. The first is a 1‑for‑15 reverse stock split intended to help the company regain compliance with Nasdaq’s $1.00 minimum bid price and support its continued listing after receiving delisting notices and a compliance extension through December 8, 2025. Based on 10,892,657 shares outstanding as of the record date, this would reduce outstanding shares to roughly 726,177, with holders receiving one whole share in lieu of any fractional share. The second proposal seeks approval under Nasdaq rules to issue up to $10,000,000 of common stock under a Standby Equity Purchase Agreement with Yorkville, which could exceed the 20% issuance cap and may be deemed a change of control. The third proposal would allow adjournment of the meeting to solicit more votes if needed.
Predictive Oncology Inc. filed a current report stating that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The company used this filing to formally furnish the press release, which is included as Exhibit 99.1. This gives investors access to the detailed quarterly performance information through the attached exhibit rather than within the body of the report.
Predictive Oncology applies AI and a proprietary biobank of 150,000+ tumor samples to support oncology drug discovery and now operates as a single segment focused on AI-driven cancer-therapy development after reclassifying its Birmingham and Eagan businesses to discontinued operations.
The company reported total assets of $3.44M and total liabilities of $5.09M as of June 30, 2025, producing a stockholders' deficit of $(1.65M). Cash and cash equivalents were $506,078. For the six months ended June 30, 2025 the company recorded revenue of $112,992, a net loss of $4.51M (continuing operations loss of $4.26M), and net cash used in continuing operating activities of $4.28M. The company sold its Eagan assets for $625,000 (plus assumed liabilities) and closed related discontinued operations.
Management discloses substantial doubt about the company’s ability to continue as a going concern without additional financing. Nasdaq notified the company of noncompliance but a Hearings Panel granted an extension through December 8, 2025. Subsequent events include a standby equity purchase agreement providing the right to sell up to $10.0M of common stock subject to conditions and a proposed 1-for-15 reverse stock split subject to stockholder approval.
Predictive Oncology (POAI) has scheduled a 2025 Special Meeting to vote on three board-backed items:
- Reverse Stock Split 1-for-15 – designed to lift the share price above Nasdaq’s US$1.00 minimum and remedy bid-price and equity deficiencies. Nasdaq has granted an extension until 8 Dec 2025.
- Nasdaq Proposal – authorize issuance of up to US$10 million in common stock under a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. Yorkville can purchase shares over 36 months at VWAP minus 4 %, potentially exceeding the 19.99 % “Exchange Cap.”
- Adjournment Proposal – permits the meeting to be postponed to secure sufficient votes.
The reverse split will consolidate every 15 shares into one, reduce the shares outstanding accordingly and round up fractional entitlements. While the move should improve marketability and preserve the Nasdaq listing, it increases the pool of authorized but unissued shares, raising dilution and anti-takeover concerns. The SEPA offers flexible working-capital financing, yet further share sales will dilute existing holders and depend on shareholder approval to lift the cap.
Failure to pass Proposals 1 or 2 risks delisting and limits access to the full SEPA facility. The board unanimously recommends voting FOR all three proposals.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
